Shares of LIVZON PHARMA (01513) rose nearly 4% during the late trading session. At the time of writing, the stock was up 3.62% to HK$26.34, with a turnover of HK$18.49 million.

The move follows the company's recent announcement that the marketing application for its Class 1 innovative biologic drug, Laikang Qita Monoclonal Antibody, for the treatment of ankylosing spondylitis, has been formally accepted by the National Medical Products Administration.

This marks the second New Drug Application (NDA) acceptance for this drug, following the prior acceptance and inclusion in the priority review pathway for its psoriasis indication. Public information indicates that Laikang Qita Monoclonal Antibody is the first China-developed IL-17A/F dual-target antibody.

As subsequent indications are gradually approved, Laikang Qita Monoclonal Antibody is expected to further enrich LIVZON PHARMA's product portfolio in the autoimmune disease field, enhancing the company's competitiveness in the global biopharmaceutical market.